Table 3.
Change of secondary outcome measures in risperidone long acting injection and paliperidone palmitate groups
| RLAI group | PP group | Difference in change between groups | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change | Baseline | Change | p | Partial eta-squared | 95%CI | |||||
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | ||||
| SWNS | |||||||||||
| Total score | 79.09 | 19.93 | −.09 | 19.58 | 67.00 | 19.25 | 3.20 | 7.36 | .655 | .012 | −9.07 to 14.06 |
| Mental function | 16.00 | 4.52 | −.18 | 4.58 | 12.60 | 3.92 | .70 | 3.02 | .990 | < .001 | −3.74 to 3.69 |
| Self-control | 15.45 | 4.44 | 1.46 | 5.18 | 14.20 | 3.49 | .40 | 3.13 | .267 | .072 | −1.91 to 6.48 |
| Emotional regulation | 16.55 | 4.06 | −1.91 | 3.73 | 13.20 | 3.77 | 1.80 | 1.93 | .034* | .238 | −5.90 to -.26 |
| Physical functioning | 15.64 | 5.32 | −1.27 | 5.95 | 13.80 | 4.54 | .30 | 2.50 | .825 | .003 | −4.89 to 3.951 |
| Social integration | 15.36 | 5.63 | −.36 | 4.37 | 13.40 | 4.86 | .00 | 2.16 | .492 | .028 | −1.69 to 3.38 |
| PANSS | |||||||||||
| Total | 83.00 | 19.88 | −5.09 | 8.18 | 78.10 | 21.02 | −1.70 | 5.08 | .349 | .049 | −8.90 to 3.31 |
| Positive | 18.64 | 5.32 | −2.00 | 2.65 | 16.30 | 4.72 | −.30 | 2.00 | .222 | .082 | −3.39 to .84 |
| Negative | 21.73 | 5.14 | −.73 | 1.10 | 20.10 | 6.06 | .20 | 1.62 | .136 | .119 | −2.27 to .34 |
| General psychopathology | 42.64 | 10.88 | −2.36 | 5.45 | 41.70 | 11.05 | −1.60 | 2.50 | .732 | .007 | −4.39 to 3.14 |
| DIEPSS total | 2.55 | 2.60 | −.09 | .30 | 0.90 | 1.28 | .30 | 1.06 | .220 | .082 | −1.23 to .30 |
| Total antipsychotic dosea | 432 | 112.6 | −12.6 | 18.6 | 342 | 94.7 | −26.8 | 52.0 | .651 | .012 | −30.41 to 47.43 |
aChlorpromazine-equivalent dose, *p < .05